Pulse Biosciences Inc (PLSE)

Currency in USD
14.75
-0.27(-1.80%)
Closed·
After Hours
14.750.00(0.00%)
·
PLSE Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Earnings results expected in 9 days
Fair Value
Day's Range
14.1714.92
52 wk Range
13.5025.00
Key Statistics
Prev. Close
15.02
Open
14.75
Day's Range
14.17-14.92
52 wk Range
13.5-25
Volume
159.41K
Average Volume (3m)
169.67K
1-Year Change
-0.54%
Book Value / Share
1.76
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
PLSE Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
22.00
Upside
+49.15%
Members' Sentiments
Bearish
Bullish
ProTips
Net income is expected to grow this year

Pulse Biosciences Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Strong Buy
Moving Averages
Sell

Pulse Biosciences Inc Company Profile

Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a novel Nanosecond Pulsed-Field Ablation delivery platform to treat benign lesions of the skin; CellFX nsPFA Percutaneous Electrode system for soft tissue ablation in surgical setting; CellFX nsPFA Cardiac Clamp designed for use in surgical treatment of atrial fibrillation (AF); CellFX nsPFA 360° Cardiac Catheter designed to provide a circumferential, or circular, ablation in a single treatment cycle; and The CellFX Consol, a tunable, software-enabled, and console-based platform designed to accommodate the clinical workflow preferred by physicians. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Miami, Florida.

Pulse Biosciences Inc Earnings Call Summary for Q1/2025

  • Pulse Biosciences reported Q1 2025 GAAP net loss of $16.8M, with stock up 0.3% after hours to $16.90
  • Company advancing nanosecond pulse field ablation technology, plans revenue generation in H2 2025
  • Total GAAP costs up $7.4M YoY to $18M; raised $14M through warrant exercises
  • CEO highlights NSPFA as 'truly disruptive,' with commercial adoption expected late 2025
  • InvestingPro projects profitability in 2025 with EPS forecast of $1.71
Last Updated: 08/05/2025, 22:24
Read Full Transcript

Compare PLSE to Peers and Sector

Metrics to compare
PLSE
Peers
Sector
Relationship
P/E Ratio
−16.5x−3.3x−0.5x
PEG Ratio
0.61−0.180.00
Price/Book
8.4x2.8x2.6x
Price / LTM Sales
-3.7x3.3x
Upside (Analyst Target)
49.2%36.2%45.4%
Fair Value Upside
Unlock6.2%7.7%Unlock

Analyst Ratings

1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 22.00
(+49.15% Upside)

Earnings

Latest Release
May 08, 2025
EPS / Forecast
-0.25 / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

PLSE Income Statement

People Also Watch

48.91
DIOD
-0.93%
27.070
SMMT
+2.65%
7.900
CAPR
-3.42%
26.93
SATS
-17.37%
7.60
ASPN
-0.78%

FAQ

What Stock Exchange Does Pulse Biosciences Trade On?

Pulse Biosciences is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Pulse Biosciences?

The stock symbol for Pulse Biosciences is "PLSE."

What Is the Pulse Biosciences Market Cap?

As of today, Pulse Biosciences market cap is 992.29M.

What Is Pulse Biosciences's Earnings Per Share (TTM)?

The Pulse Biosciences EPS (TTM) is -0.99.

When Is the Next Pulse Biosciences Earnings Date?

Pulse Biosciences will release its next earnings report on 11 Aug 2025.

From a Technical Analysis Perspective, Is PLSE a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Pulse Biosciences Stock Split?

Pulse Biosciences has split 0 times.

How Many Employees Does Pulse Biosciences Have?

Pulse Biosciences has 75 employees.

What is the current trading status of Pulse Biosciences (PLSE)?

As of 03 Aug 2025, Pulse Biosciences (PLSE) is trading at a price of 14.75, with a previous close of 15.02. The stock has fluctuated within a day range of 14.17 to 14.92, while its 52-week range spans from 13.50 to 25.00.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.